- 1 Title: Thyroid Function Analysis in COVID-19: A Retrospective Study from a Single
- 2 Center
- 3 Running Head: Thyroid Analysis in COVID-19 Pneumonia
- 4 Dr. Jahanzeb Malik<sup>1\*</sup>, Dr.Asmara Malik<sup>2</sup>, Dr. Muhammad Javaid<sup>1</sup>, Dr. Tayyaba Zahid<sup>1</sup>,
- 5 Dr. Uzma Ishaq<sup>3</sup>, Dr. Muhammad Shoaib<sup>4</sup>
- 6 1 Department of Cardiology, Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi,
- 7 **46000, Pakistan**
- 8 2 Department of Public Health, National University of Medical Sciences, Mall road,
- 9 Saddar, Rawalpindi, 46000, Pakistan
- 10 3 Department of Pathology, Foundation University Medical College, Islamabad, 44000,
- 11 Pakistan
- 12 3 Department of Cardiology, Pakistan Institute of Medical Sciences, Islamabad, 44000,
- 13 Pakistan
- 14
- 15 Corresponding Author/Proofs
- 16 Dr. Jahanzeb Malik, MBBS, FCPS Cardiology, Senior Registrar Cardiology
- 17 Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi, 46000, Pakistan
- 18 <u>Heartdoc86@gmail.com</u>
- 19 Contact: 00923215668347
- 20 Word count: 2803
- 21 Keywords: COVID-19, Thyroid diseases, Thyroid-Stimulating Hormone, Triiodothyronine
- 22 Conflict of interest: None to declare
- 23 Funding: None

2

## 24 Abstract

#### 25 Background and Objective

Coronavirus disease 2019 (COVID-19) is an on-going epidemic with a multitude of long-ranging effects on the physiological balance of the human body. It can cause several effects on thyroid functions as well. We aimed to assess the lasting sequelae of COVID-19 on thyroid hormone and the clinical course of the disease as a result.

#### 30 Methods

Out of 76 patients, 48 patients of COVID-19 positive and 28 patients of COVID-19 negative

32 polymerase chain reaction (PCR) were assessed for thyroid functions, IL-6, and Procalcitonin

between moderate, severe, and critical pneumonia.

### 34 **Results**

- 35 Seventy-five percent of patients with COVID-19 had thyroid abnormalities and higher IL-6
- 36 levels (76.10  $\pm$  82.35 vs. 6.99  $\pm$  3.99, 95% CI 52.18-100.01, P-value <0.01). Logistic regression
- analysis suggested TT3 (P-value 0.01), IL-6 (P-value <0.01), and Procalcitonin (P-value 0.03) as
- independent risk factors for COVID-19. ROC curve demonstrated IL-6 as the most sensitive
- marker (P-value <0.01), and TT3, and Procalcitonin as the predictor for COVID-19 disease.

### 40 Conclusion

- 41 This pilot study from Pakistan demonstrates that changes in serum TSH and TT3 levels may be
- 42 important manifestations of the courses of COVID-19 pneumonia.
- 43 Keywords: COVID-19, Thyroid diseases, Thyroid-Stimulating Hormone, Triiodothyronine

44

3

### 46 Introduction

47 The on-going pandemic of coronavirus disease 2019 (COVID-19) has been found to have multiple long-ranging effects on the normal physiological balance of the human body. Complex 48 49 and severe effects on human organ systems are being identified rapidly, including the 50 respiratory, gastric, circulatory, immune, renal, hepatic, cardiac, and hematological systems. 51 Literature on COVID-19 affecting human thyroid function is increasing gradually and the 52 understanding of thyroid dysfunction and its mechanism is growing. The expression of ACE2 53 combined with transmembrane protease serine 2 (TMPRESS2) is the key cellular complex for the virus to infect the human cells and interestingly both expression levels are present in the 54 thyroid gland, even more than the lungs.<sup>1</sup> 55

COVID-19 initiates an immune response over-activity leading to release of pro-56 inflammatory cytokines, particularly interleukin-6 (IL-6), which leads to overt thyroid 57 58 dysfunction by disruption of desiodases and thyroid transport proteins. Levels of T3 is inversely 59 proportional to IL-6 with a modest decrease of TSH and T4. This abnormality is described as sick euthyroid syndrome.<sup>2,3</sup> During the course of COVID-19 pneumonia, thyrotoxicosis may be 60 61 caused secondary to graves thyroiditis or subacute inflammatory thyroiditis. It can be complicated by arrhythmias or thromboembolic episodes. Hence, abnormalities of thyroid 62 dysfunction are important to evaluate in COVID-19.<sup>4</sup> 63

We conducted a retrospective, cross-sectional study of COVID-19 patients in our hospital in Rawalpindi, Pakistan, compared with a matched cohort of non-COVID-19 patients. Our objectives were to determine if COVID-19 caused acute and subacute thyroid abnormalities, as determined by a diagnostic assessment of thyroid function, and whether thyroid dysfunction leads to a more severe clinical course of COVID-19 in a South Asian population.

4

## 69 Materials and Methods

This retrospective study was approved by the ethical committee at our institute following
the World Medical Association Declaration of Helsinki. Patients were considered for inclusion
with positive high resolution computed tomography (HRCT) for SARS-CoV-2.

73 The medical records of all the patients admitted at our institute from April 2020 to July 74 2020 with pneumonia were retrospectively examined. Patients with a history of thyroid disease, 75 without assessment and follow-up of thyroid function and IL-6/procalcitonin, pregnancy, and mild COVID-19 infections were excluded from the study. A total of 76 patients were enrolled in 76 77 this study. Forty-eight with COVID-19 and 28 with non-COVID-19 pneumonia fulfilled the 78 criteria for this study. They were included in this study after written informed consent from the patients. Attrition bias was taken into account. All the tests were taken on initial blood sampling 79 (Day 1) before steroid treatment, IL-6 receptor antagonists, and remdesivir and after three 80 81 months' (Day 90) follow-up so that no confounding factors produced a bias in this study. This group was screened for underlying thyroid disease or any other medical history that can affect 82 83 thyroid function.

All the cases were labeled as moderate, severe, or critical based on the clinical symptoms, laboratory tests, and chest computed tomography (CT) scans. Moderate and severe cases were classified as having pneumonia manifestations seen on imaging, respiratory rate of  $\geq 30$ breaths/min, and oxygen saturation  $\leq 90\%$  at rest. Critical cases were labeled as those requiring mechanical ventilation due to respiratory failure, other organ failures that require intensive care unit, and the presence of shock.

All patients included in the study had their thyroid functions, including thyroidstimulating hormone (TSH), total triiodothyronine (TT3), serum total thyroxine (TT4),

92	procalcitonin, and IL-6 levels done via electrochemiluminescent immunoassay (ECLIA) in the
93	Elecsys® 2010 immunoassay system. All the parameters were analyzed and compared between
94	the COVID-19 and the control group.
95	Data were analyzed with the Statistical Package for the Social Sciences (SPSS) version
96	26 (IBM Corp., Armonk, NY). Quantitative data were presented as mean ± standard deviation
97	(SD) and qualititative data in frequency and percentages. Both groups were compared using the
98	students' t-test and Chi-square when feasible. Stem and leaf plots were calculated to see the
99	distribution of continuous variables. A receiver operating characteristic (ROC) curve was
100	calculated for thyroid function tests and the acute phase reactants to find out sensitivity and
101	specificity of the lab parameters in COVID-19 pneumonia. Confidence interval (CI) were
102	presented for the lab parameters in all groups. A P-value of less than 0.05 was considered
103	significant.
104	
4.05	
105	
106	
107	
107	
108	
109	
105	
110	
111	

6

# 112 **Results**

- 113 During the course of our study, a total of 76 patients were enrolled. Forty-eight with confirmed
- 114 COVID-19 and 28 patients with non-COVID-19 pneumonia with their thyroid profiles done
- 115 were also included as controls. Patient demographics and characteristics of pneumonia in both
- the groups were evenly matched. They are differentiated in **Table 1**.
- 117 **Table 1.** Demographics and severity of pneumonia

Demographics	COVID (n=48)	Non-COVID (n=28)	P-value
Age (Mean ± SD)	51 ± 19.30	64.79 ± 11.44	0.68
Male (%)	31(64.6%)	15(53.6%)	0.34
Severity			
Moderate	22(45.8%)	8(28.6%)	0.13
Severe	9(18.8%)	10(35.7%)	0.09
Critical	17(35.4%)	10(35.7%)	0.97

118

Our examination of the thyroid function analysis suggested that 36 (75%) patients with COVID-19 pneumonia had abnormal thyroid functions while 24 (85.7%) patients were detected with non-COVID-19 pneumonia. IL-6 was significantly higher in COVID-19 group as compared with non-COVID-19 group (76.10  $\pm$  82.35 vs. 6.99  $\pm$  3.99, 95% CI 52.18-100.01, P-value <0.01).

7

124	At follow-up, there was a downtrend in IL-6 levels in both groups ( $14.16 \pm 16.58$ vs. $4.88$
125	$\pm$ 2.66, P-value <0.01). Procalcitonin levels were statistically significant between both the groups
126	(P-value <0.01). IL-6 was associated with abnormal TSH, TT3, and TT4 levels (P-value <0.01).
127	Table 2 differentiates thyroid profile and acute phase reactants in both COVID-19 and non-
128	COVID-19 group.

129 **Table 2.** Comparison of thyroid functions and acute phase reactants in both groups

Tests	COVID		95% CI	Non-		95% CI	P-value
	( <b>n=48</b> )			COVID			
				(n=28)			
	At	At		At	At		
	admission	Follow-		admissio	Follow		
		up		n	-up		
IL6	76.10 ±	14.16 ±	52.18-	6.99 ±	4.88 ±	5.44-8.54	< 0.01
(pg/mL)	82.35	16.58	100.01	3.99	2.66		
Procalcitoni	0.36 ±	0.14 ±	0.21-0.51	0.06 ±	0.05 ±	0.01-0.11	< 0.01
n (mcg/L)	0.52	0.32		0.12	0.08		
TSH	1.48 ±	1.11 ±	0.76-2.20	1.73 ±	1.65 ±	0.93-2.53	<0.01
(mIU/L)	2.47	1.15		2.06	1.73		
TT3	74.62 ±	89.98 ±	64.83-	100.21 ±	101.86	82.59-	<0.01
(ng/dL)	33.71	35.15	84.42	45.46	±	117.84	
					40.90		

8

TT4	6.67 ±	6.79 ±	5.87-7.46	6.43 ±	9 ±	5.48-7.38	0.11
(mcg/dL)	2.74	2.37		2.44	2.77		

130

131 Comparison of TSH and TT3 shows significantly lower mean values in severe COVID-132 19 infection as compared with critical patients ( $0.32 \pm 0.22$  vs.  $2.32 \pm 3.44$ , P-value <0.01) 133 (67.44 ± 34.51 vs. 77.12 ± 48.22, P-value <0.01). A comparison of lab parameters among 134 different classes of pneumonia is shown in **Table 3**.

135 **Table 3.** Comparison of lab parameters between severity of disease. **\*P-value <0.05** 

Tests	Moderate		Severe		Critical	
	Covid	Non-	Covid	Non-	Covid	Non-
	(n=22)	covid	( <b>n=9</b> )	covid	(n=17)	covid
		( <b>n=8</b> )		(n=10)		(n=10)
TSH	1.31 ±	1.28 ±	0.32 ±	2.34 ±	2.32 +	1.49 ±
	1.05%					
	1.87*	0.93	0.22	2.61	3.44*	2.14*
Follow-up	1.13 ±	1.68 ±	0.34 ±	1.27 ±	1.50 ±	2 ±
	1.01*	1.09	0.14	0.76	1.44*	2.68*
TT3	75.64 ±	111 ±	67.44 ±	95.50 ±	77.12 ±	96.30 ±
	17.03*	42.93*	34.51	51.08*	48.22*	44.86*
Follow-up	86.14 ±	117.38	92.44 ±	88.70 ±	93.65 ±	102.60
		±				±

9

	17.67*	38.23*	42.68	32.66*	47.66*	49.08*
TT4	6.91 ±	7.88 ±	7.44 ±	6 ±	5.94 ±	5.70 ±
	2.61*	2.16	1.81*	2.40	3.24*	2.40*
Follow-up	7.23 ±	11.25 ±	7.44 ±	9.60 ±	5.88 ±	6.60 ±
	2.15*	2.91	1.74*	1.50	2.73*	1.71*

136

Logistic regression was performed to determine how levels of thyroid functions and phase reactants affect the risk of COVID-19 pneumonia. The model suggested TT3 (P-value 0.01), IL-6 (P-value <0.01), and Procalcitonin (P-value 0.03) as independent risk factors for COVID-19. None of the patients received thyroid hormone replacement therapy, and the levels of all the thyroid hormones returned to normal after recovery.

The stem and leaf plot was generated to demonstrate the distribution of the lab parameters. It is shown in Figure 1. The area under the ROC (AUC) for IL-6 and Procalcitonin was 0.941 (95% CI 0.89-0.98, P-value <0.01) and 0.745 (95% CI 0.00-0.63, P-value <0.01), respectively. TT3 was a predictor of COVID-19 pneumonia with AUC 0.283 (95% CI 0.15-0.40, P-value <0.01). Figure 1 suggests that thyroid function tests are not good predictors for progression to severe COVID-19 infection. The ROC curve indicated IL-6 to be inversely proportional to TT3.

149 **Figure 1. ROC curve for lab parameters** 

Differentiation of sensitivity and specificity is shown in Table 4 and Multivariate analysis in
Table 5.

10

### **Table 4.** Sensitivity and specificity in predicting COVID-19

Test	Area under	Sensitivity	Specificity	P-value
	the curve			
IL6	0.941	0.979	0.357	<0.01
Procalcitonin	0.745	0.667	0.357	<0.01
TSH	0.378	0.438	0.679	0.07
TT3	0.283	0.375	0.786	<0.01
TT4	0.542	0.479	0.393	0.54

153

154

155

156 Table 5. Multivariate analysis of lab parameters in moderate, severe, and critical pneumonia

Moderate					
Pneumonia					
Lab	В	SE	Wald	OR, 95% CI	P-value
Parameters					
IL-6	0.02	.01	3.49	1.67, 10.46-	0.06
				25.00	
TT3	0.00	.00	0.64	0.12, 73.81-	0.42
				96.32	
TT4	-0.24	.12	4.20	23.81, 6.23-	0.04
				8.10	
TSH	0.14	.14	0.91	0.67, 0.69-	0.33
				1.92	
Procalcitonin	2.73	1.73	2.49	0.15, 0.28-	0.11
				0.12	
Severe					
Pneumonia					
IL-6	0.00	0.00	1.53	0.32, 16.32-	0.21

4	4
-	-

# **Discussion**

12

167 The results of our study showed that TSH was raised in moderately and critically affected 168 patients of COVID-19 as compared to non-COVID-19 patients. Additionally, TT3 levels were raised significantly more at follow-up in COVID-19 patients than non-COVID-19 patients with 169 170 little to no discernable effect on TT4 levels. Our findings are in contrast to a similar retrospective study from China, which found lower TSH levels in more severely affected patients of COVID-171 19 and a study from Italy in which COVID-19 patients were found to have thyrotoxicosis after a 172 confirmatory diagnosis of COVID-19.<sup>5,6</sup> Although all thyroid function tests returned close to 173 174 baseline at follow-up in both the Chinese and Italian studies, our study sample showed an outlier in having raised TT3 levels across all three levels of severity of COVID-19. This is of great 175 concern, particularly when paired with the lasting damage to cardiac and respiratory systems 176 which has been documented with regards to COVID-19.<sup>7</sup> Cardiac abnormalities secondary to 177 thyroid abnormalities may worsen when regarded in the context of post-infectious sequelae. 178

179 The thyroid gland is a major organ in maintaining many long term functions of the body, 180 in particular, cardiovascular, respiratory, and catabolic tasks, which is why many lower-income 181 countries have implemented salt iodination as a way to counter the consequences of iodinedeficient thyroid disorders.<sup>8,9</sup> As an emerging disease, COVID-19 has taken a devastating toll in 182 lower-middle-income countries, with seemingly no end in sight to the rising death toll which, at 183 the time of this writing, stands to cross more than 1, 000, 000.<sup>10</sup> As the pandemic rages on, more 184 and more insights are emerging into not just the multi-systemic involvement of the virus, but its 185 impact on disrupting the endocrine system-- with more long-term effects-- can also no longer be 186 overlooked, particularly in the context of countries already struggling with prevalent endocrine 187 diseases.<sup>2</sup> 188

13

In Pakistan, the prevalence of hyperthyroidism and subclinical hyperthyroidism is 5.1% and 5.8%, respectively, and hypothyroidism is at 4.1%. Even though hyperthyroid conditions are relatively rare in Pakistan.<sup>4</sup> Our prevalence seems to be well above the prevalence of both disorders in Europe (0.7%) and the United States (0.5%), while in our closest neighbor, India, subclinical and overt hyperthyroidism were present in 1.6% and 1.3%, respectively and hypothyroidism is comparable at 3.4%.<sup>9,11</sup>

195 Unlike other countries where COVID-19 has decimated population bases, Pakistan seems to have emerged relatively unscathed from the pandemic.<sup>12</sup> However, given the thyroid 196 abnormalities which have emerged in our study sample, it would seem that the long-term effects 197 of COVID-19, particularly with regards to follow-up of critically ill patients, may be overlooked 198 especially for elderly patients, in which the symptoms of excessive TT3 in circulation—body 199 200 aches, confusion, increased heart rate-may simply be dismissed as recovery from a viral 201 infection. Concurrently, a thyroid storm with raised inflammatory markers also has overlapping signs and symptoms with the cytokine storm characteristic of COVID-19 worsening in critically 202 ill patients.<sup>8,13,14,15</sup> Indeed, precedent for the effect of a previous coronavirus affecting the thyroid 203 204 was established by post-mortem studies of thyroid samples from patients infected with SARS during the 2002 outbreak.<sup>16</sup> This immunogenic and hormonal overlap of a novel disease may 205 206 further complicate the management and recovery of COVID-19, as corticosteroids used in the 207 treatment of severe COVID-19 may inadvertently cause auto-immune damage to the thyroid gland.<sup>3,16</sup> 208

Our study was limited to a small pool of consenting patients and less duration of followup. One other shortcoming was that free T3, free T4, and other pituitary hormones were not assessed at admission and follow-up due to the retrospective nature of the study. Our institute

212	being a tertiary care, it received a higher than moderately severe COVID-19 cases. Hence,
213	patients with mild COVID-19 were not assessed for thyroid functions.
214	
215	
216	
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	

15

# 228 Conclusion

229	To the best of our knowledge, this is the first study regarding thyroid disease in Pakistan.
230	This retrospective study provides solid evidence of the high risk of altered thyroid function after
231	COVID-19 pneumonia. We believe our study represents an important direction of exploration of
232	the true cost of the disease, where the overt crises of COVID-19 may mask an emerging crisis of
233	long-term endocrine dysfunctions. Clinical vigilance must be practiced by physicians when
234	monitoring for recovery from COVID-19 for signs and symptoms of thyroid hormone
235	disruptions, particularly in patients of South Asian descent. Further prospective studies will
236	clarify the clinical and prognostic relevance of abnormal behavior of the thyroid gland with
237	COVID-19.
238	
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	
250	

16

2	5	1
2	J	т

- 252 **Conflict of Interest**
- 253 None to declare
- 254 **Source of funding:**
- 255 None

### 256 Ethical considerations

- 257 All patients were enrolled for this study after an informed written consent. Ethical review board
- of Foundation University gave approval regarding usage of the patient data (FFH/37/DCA/2020),
- in accordance with the ethical standards of the Declaration of Helsinki.

### 260 Acknowledgement

- 261 None
- 262
- 263
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273

17

274

### 275 **<u>References</u>**

- 276 1. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the
- thyroid gland: an update [published online ahead of print, 2020 Nov 25]. Rev Endocr Metab
- 278 Disord. 2020;1-13. doi:10.1007/s11154-020-09615-z
- Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential
   vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol.
   2020;38(1):1-9. doi:10.12932/AP-200220-0772
- 3. Wang W., Ye Y.X., Yao H. Evaluation and observation of serum thyroid hormone and
  parathyroid hormone in patients with severe acute respiratory syndrome. J Chin
  Antituberculous Assoc. 2003;25:232–234.
- Khan A, Khan MMA, Akhtar S. Thyroid Disorders, Etiology and Prevalence. J of Medical
   Sciences. 2002; 2(2):89–94. doi: 10.3923/jms.2002.89.94
- 5. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A
  Retrospective Study. Thyroid. 2020 Jul 10. doi: 10.1089/thy.2020.0363. Epub ahead of print.
- 6. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients
  with COVID-19: the THYRCOV study. Eur J Endocrinol. 2020 Oct;183(4):381-387. doi:
  10.1530/EJE-20-0335. PMID: 32698147.
- Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and
  Cardiovascular Disease. Circulation. 2020 May 19;141(20):1648-1655. doi:
  10.1161/CIRCULATIONAHA.120.046941.

295	8.	Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. Endocrine.
296		2020;68(3):471-474. doi:10.1007/s12020-020-02364-8

- 9. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE.
- Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018
- 299 May;14(5):301-316. doi: 10.1038/nrendo.2018.18.
- 10. Noor AU, Maqbool F, Bhatti ZA, Khan AU. Epidemiology of CoViD-19 Pandemic:
  Recovery and mortality ratio around the globe. Pak J Med Sci. 2020;36(COVID19-S4):S79S84. doi:10.12669/pjms.36.COVID19-S4.2660
- 303 11. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological
   304 perspective. Indian J Endocrinol Metab. 2011;15(Suppl 2):S78-S81. doi:10.4103/2230 305 8210.83329
- Abid K, Bari YA, Younas M, Tahir Javaid S, Imran A. Progress of COVID-19 Epidemic in
  Pakistan. Asia Pac J Public Health. 2020;32(4):154-156. doi:10.1177/1010539520927259
- 308 13. Dasgupta A, Kalhan A, Kalra S. Long term complications and rehabilitation of COVID-19
  309 patients. J Pak Med Assoc. 2020;70(Suppl 3)(5):S131-S135. doi:10.5455/JPMA.32
- 14. Bellastella G, Maiorino MI, Esposito K. Endocrine complications of COVID-19: what
  happens to the thyroid and adrenal glands?. J Endocrinol Invest. 2020;43(8):1169-1170.
  doi:10.1007/s40618-020-01311-8
- 313 15. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, Latrofa F. Is Subacute
  314 Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a

- 315 Case Series. J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa537. doi:
  316 10.1210/clinem/dgaa537.
- 317 16. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute Thyroiditis After
- 318 Sars-COV-2 Infection. J Clin Endocrinol Metab. 2020;105(7):dgaa276.
- doi:10.1210/clinem/dgaa276



